Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 430 entries
Sorted by: Best Match Show Resources per page
Moxifloxacin-Induced Immune-Mediated Thrombocytopenia in a Chronic Kidney Disease Patient Receiving Hemodialysis.

The Annals of pharmacotherapy

Mailman JF, Stigant C, Martinusen D.
PMID: 24687544
Ann Pharmacother. 2014 Jul;48(7):919-922. doi: 10.1177/1060028014529929. Epub 2014 Mar 31.

OBJECTIVE: To alert clinicians to a serious complication from a commonly prescribed medication, moxifloxacin.CASE SUMMARY: A 65-year-old male, septic, hemodialysis patient developed thrombocytopenia following exposure to vancomycin, ceftazidime, and moxifloxacin. Drug-specific immunoglobulin testing showed positive autoantibodies against only moxifloxacin,...

Cite
Mailman JF, Stigant C, Martinusen D. Moxifloxacin-Induced Immune-Mediated Thrombocytopenia in a Chronic Kidney Disease Patient Receiving Hemodialysis. Ann Pharmacother. 2014;48(7):919-922doi: 10.1177/1060028014529929.
Mailman, J. F., Stigant, C., & Martinusen, D. (2014). Moxifloxacin-Induced Immune-Mediated Thrombocytopenia in a Chronic Kidney Disease Patient Receiving Hemodialysis. The Annals of pharmacotherapy, 48(7), 919-922. https://doi.org/10.1177/1060028014529929
Mailman, Jonathan F, et al. "Moxifloxacin-Induced Immune-Mediated Thrombocytopenia in a Chronic Kidney Disease Patient Receiving Hemodialysis." The Annals of pharmacotherapy vol. 48,7 (2014): 919-922. doi: https://doi.org/10.1177/1060028014529929
Mailman JF, Stigant C, Martinusen D. Moxifloxacin-Induced Immune-Mediated Thrombocytopenia in a Chronic Kidney Disease Patient Receiving Hemodialysis. Ann Pharmacother. 2014 Jul;48(7):919-922. doi: 10.1177/1060028014529929. Epub 2014 Mar 31. PMID: 24687544.
Copy Download .nbib Format: NLM
Everolimus in Breast Cancer: The Role of the Pharmacist.

The Annals of pharmacotherapy

Dorris JR, Jones S.
PMID: 25007922
Ann Pharmacother. 2014 Sep;48(9):1194-1201. doi: 10.1177/1060028014542415. Epub 2014 Jul 09.

OBJECTIVE: To highlight the potential role of pharmacists in facilitating use of everolimus in breast cancer and increase practitioner knowledge of everolimus therapy to enhance patient outcomes.DATA SOURCES: A PubMed (1966 to May 2013) search included the terms everolimus,...

Cite
Dorris JR, Jones S. Everolimus in Breast Cancer: The Role of the Pharmacist. Ann Pharmacother. 2014;48(9):1194-1201doi: 10.1177/1060028014542415.
Dorris, J. R., & Jones, S. (2014). Everolimus in Breast Cancer: The Role of the Pharmacist. The Annals of pharmacotherapy, 48(9), 1194-1201. https://doi.org/10.1177/1060028014542415
Dorris, John R, and Jones, Suzanne. "Everolimus in Breast Cancer: The Role of the Pharmacist." The Annals of pharmacotherapy vol. 48,9 (2014): 1194-1201. doi: https://doi.org/10.1177/1060028014542415
Dorris JR, Jones S. Everolimus in Breast Cancer: The Role of the Pharmacist. Ann Pharmacother. 2014 Sep;48(9):1194-1201. doi: 10.1177/1060028014542415. Epub 2014 Jul 09. PMID: 25007922.
Copy Download .nbib Format: NLM
Corrigendum.

The Annals of pharmacotherapy

[No authors listed]
PMID: 26872708
Ann Pharmacother. 2016 Mar;50(3):NP1. doi: 10.1177/1060028016634252.

No abstract available.

Cite
Corrigendum. Ann Pharmacother. 2016;50(3):NP1doi: 10.1177/1060028016634252.
(2016). Corrigendum. The Annals of pharmacotherapy, 50(3), NP1. https://doi.org/10.1177/1060028016634252
"Corrigendum." The Annals of pharmacotherapy vol. 50,3 (2016): NP1. doi: https://doi.org/10.1177/1060028016634252
Corrigendum. Ann Pharmacother. 2016 Mar;50(3):NP1. doi: 10.1177/1060028016634252. PMID: 26872708.
Copy Download .nbib Format: NLM
Anaphylactic Shock Following Repeated Rasburicase Treatment.

The Annals of pharmacotherapy

Alaya S, Mofredj A, Darmon N, Tassaioust K, Mrabet A.
PMID: 29095045
Ann Pharmacother. 2018 Mar;52(3):295-296. doi: 10.1177/1060028017740599. Epub 2017 Nov 02.

No abstract available.

Cite
Alaya S, Mofredj A, Darmon N, et al. Anaphylactic Shock Following Repeated Rasburicase Treatment. Ann Pharmacother. 2017;52(3):295-296doi: 10.1177/1060028017740599.
Alaya, S., Mofredj, A., Darmon, N., Tassaioust, K., & Mrabet, A. (2018). Anaphylactic Shock Following Repeated Rasburicase Treatment. The Annals of pharmacotherapy, 52(3), 295-296. https://doi.org/10.1177/1060028017740599
Alaya, Sami, et al. "Anaphylactic Shock Following Repeated Rasburicase Treatment." The Annals of pharmacotherapy vol. 52,3 (2018): 295-296. doi: https://doi.org/10.1177/1060028017740599
Alaya S, Mofredj A, Darmon N, Tassaioust K, Mrabet A. Anaphylactic Shock Following Repeated Rasburicase Treatment. Ann Pharmacother. 2018 Mar;52(3):295-296. doi: 10.1177/1060028017740599. Epub 2017 Nov 02. PMID: 29095045.
Copy Download .nbib Format: NLM
Antiretroviral and Medication Errors in Hospitalized HIV-Positive Patients.

The Annals of pharmacotherapy

Li EH, Foisy MM.
PMID: 24811394
Ann Pharmacother. 2014 Aug;48(8):998-1010. doi: 10.1177/1060028014534195. Epub 2014 May 08.

OBJECTIVE: To summarize the literature regarding antiretroviral and other medication errors in hospitalized HIV-positive patients and to discuss potential interventions and solutions that have been studied to minimize drug error.DATA SOURCES: A systematic search of MEDLINE, PubMed, and EMBASE...

Cite
Li EH, Foisy MM. Antiretroviral and Medication Errors in Hospitalized HIV-Positive Patients. Ann Pharmacother. 2014;48(8):998-1010doi: 10.1177/1060028014534195.
Li, E. H., & Foisy, M. M. (2014). Antiretroviral and Medication Errors in Hospitalized HIV-Positive Patients. The Annals of pharmacotherapy, 48(8), 998-1010. https://doi.org/10.1177/1060028014534195
Li, Emily H, and Foisy, Michelle M. "Antiretroviral and Medication Errors in Hospitalized HIV-Positive Patients." The Annals of pharmacotherapy vol. 48,8 (2014): 998-1010. doi: https://doi.org/10.1177/1060028014534195
Li EH, Foisy MM. Antiretroviral and Medication Errors in Hospitalized HIV-Positive Patients. Ann Pharmacother. 2014 Aug;48(8):998-1010. doi: 10.1177/1060028014534195. Epub 2014 May 08. PMID: 24811394.
Copy Download .nbib Format: NLM
Levomilnacipran: A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder.

The Annals of pharmacotherapy

Palmer EC, Binns LN, Carey H.
PMID: 24811398
Ann Pharmacother. 2014 Aug;48(8):1030-1039. doi: 10.1177/1060028014535074. Epub 2014 May 08.

OBJECTIVE: To provide a clinical overview of the antidepressant levomilnacipran.DATA SOURCES: Articles were identified by searching the MEDLINE, PubMed, Cochrane Library, and Clinicaltrials.gov databases through March 2014 using the keyword levomilnacipran. The manufacturer provided additional information from unpublished phase...

Cite
Palmer EC, Binns LN, Carey H. Levomilnacipran: A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder. Ann Pharmacother. 2014;48(8):1030-1039doi: 10.1177/1060028014535074.
Palmer, E. C., Binns, L. N., & Carey, H. (2014). Levomilnacipran: A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder. The Annals of pharmacotherapy, 48(8), 1030-1039. https://doi.org/10.1177/1060028014535074
Palmer, Emma C, et al. "Levomilnacipran: A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder." The Annals of pharmacotherapy vol. 48,8 (2014): 1030-1039. doi: https://doi.org/10.1177/1060028014535074
Palmer EC, Binns LN, Carey H. Levomilnacipran: A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder. Ann Pharmacother. 2014 Aug;48(8):1030-1039. doi: 10.1177/1060028014535074. Epub 2014 May 08. PMID: 24811398.
Copy Download .nbib Format: NLM
Incidence and Management of Rash in Telaprevir-Treated Patients.

The Annals of pharmacotherapy

Smith MA, Johnson HJ, Chopra KB, Dunn MA, Ulrich AM, Mohammad RA.
PMID: 24939632
Ann Pharmacother. 2014 Sep;48(9):1166-1171. doi: 10.1177/1060028014539274. Epub 2014 Jun 17.

BACKGROUND: Telaprevir-induced rash is a common, therapy-limiting adverse drug event (ADE) for patients with hepatitis c virus (HCV) infection. Given the similarity between telaprevir and simeprevir, real-world management of rash during treatment with an NS3/4A protease inhibitor and its...

Cite
Smith MA, Johnson HJ, Chopra KB, et al. Incidence and Management of Rash in Telaprevir-Treated Patients. Ann Pharmacother. 2014;48(9):1166-1171doi: 10.1177/1060028014539274.
Smith, M. A., Johnson, H. J., Chopra, K. B., Dunn, M. A., Ulrich, A. M., & Mohammad, R. A. (2014). Incidence and Management of Rash in Telaprevir-Treated Patients. The Annals of pharmacotherapy, 48(9), 1166-1171. https://doi.org/10.1177/1060028014539274
Smith, Michael A, et al. "Incidence and Management of Rash in Telaprevir-Treated Patients." The Annals of pharmacotherapy vol. 48,9 (2014): 1166-1171. doi: https://doi.org/10.1177/1060028014539274
Smith MA, Johnson HJ, Chopra KB, Dunn MA, Ulrich AM, Mohammad RA. Incidence and Management of Rash in Telaprevir-Treated Patients. Ann Pharmacother. 2014 Sep;48(9):1166-1171. doi: 10.1177/1060028014539274. Epub 2014 Jun 17. PMID: 24939632.
Copy Download .nbib Format: NLM
Use of Intravenous Lidocaine for the Treatment of Acute Pain in the Emergency Department.

The Annals of pharmacotherapy

Wiafe J, Sin B, Kramer A, Yakobi R.
PMID: 28592148
Ann Pharmacother. 2017 Oct;51(10):923. doi: 10.1177/1060028017713030. Epub 2017 Jun 07.

No abstract available.

Cite
Wiafe J, Sin B, Kramer A, et al. Use of Intravenous Lidocaine for the Treatment of Acute Pain in the Emergency Department. Ann Pharmacother. 2017;51(10):923doi: 10.1177/1060028017713030.
Wiafe, J., Sin, B., Kramer, A., & Yakobi, R. (2017). Use of Intravenous Lidocaine for the Treatment of Acute Pain in the Emergency Department. The Annals of pharmacotherapy, 51(10), 923. https://doi.org/10.1177/1060028017713030
Wiafe, Jennifer, et al. "Use of Intravenous Lidocaine for the Treatment of Acute Pain in the Emergency Department." The Annals of pharmacotherapy vol. 51,10 (2017): 923. doi: https://doi.org/10.1177/1060028017713030
Wiafe J, Sin B, Kramer A, Yakobi R. Use of Intravenous Lidocaine for the Treatment of Acute Pain in the Emergency Department. Ann Pharmacother. 2017 Oct;51(10):923. doi: 10.1177/1060028017713030. Epub 2017 Jun 07. PMID: 28592148.
Copy Download .nbib Format: NLM
Rifampin-Resistant Staphylococcus aureus Bacteremia in a Patient on Chronic Rifaximin.

The Annals of pharmacotherapy

Lewis PO, Khan I, Patel P.
PMID: 28622735
Ann Pharmacother. 2017 Jul;51(7):617-618. doi: 10.1177/1060028017701221. Epub 2017 Mar 20.

No abstract available.

Cite
Lewis PO, Khan I, Patel P. Rifampin-Resistant Staphylococcus aureus Bacteremia in a Patient on Chronic Rifaximin. Ann Pharmacother. 2017;51(7):617-618doi: 10.1177/1060028017701221.
Lewis, P. O., Khan, I., & Patel, P. (2017). Rifampin-Resistant Staphylococcus aureus Bacteremia in a Patient on Chronic Rifaximin. The Annals of pharmacotherapy, 51(7), 617-618. https://doi.org/10.1177/1060028017701221
Lewis, Paul O, et al. "Rifampin-Resistant Staphylococcus aureus Bacteremia in a Patient on Chronic Rifaximin." The Annals of pharmacotherapy vol. 51,7 (2017): 617-618. doi: https://doi.org/10.1177/1060028017701221
Lewis PO, Khan I, Patel P. Rifampin-Resistant Staphylococcus aureus Bacteremia in a Patient on Chronic Rifaximin. Ann Pharmacother. 2017 Jul;51(7):617-618. doi: 10.1177/1060028017701221. Epub 2017 Mar 20. PMID: 28622735.
Copy Download .nbib Format: NLM
Localized Bullous Eruption Away From Injection Site, Caused by Intramuscular Meglumine Antimoniate Administration.

The Annals of pharmacotherapy

Ben Salem C, Slim R, Fathallah N, Sriha B, Belajouza C.
PMID: 27048189
Ann Pharmacother. 2016 Jun;50(6):517-8. doi: 10.1177/1060028016641131. Epub 2016 Apr 05.

No abstract available.

Cite
Ben Salem C, Slim R, Fathallah N, et al. Localized Bullous Eruption Away From Injection Site, Caused by Intramuscular Meglumine Antimoniate Administration. Ann Pharmacother. 2016;50(6):517-8doi: 10.1177/1060028016641131.
Ben Salem, C., Slim, R., Fathallah, N., Sriha, B., & Belajouza, C. (2016). Localized Bullous Eruption Away From Injection Site, Caused by Intramuscular Meglumine Antimoniate Administration. The Annals of pharmacotherapy, 50(6), 517-8. https://doi.org/10.1177/1060028016641131
Ben Salem, Chaker, et al. "Localized Bullous Eruption Away From Injection Site, Caused by Intramuscular Meglumine Antimoniate Administration." The Annals of pharmacotherapy vol. 50,6 (2016): 517-8. doi: https://doi.org/10.1177/1060028016641131
Ben Salem C, Slim R, Fathallah N, Sriha B, Belajouza C. Localized Bullous Eruption Away From Injection Site, Caused by Intramuscular Meglumine Antimoniate Administration. Ann Pharmacother. 2016 Jun;50(6):517-8. doi: 10.1177/1060028016641131. Epub 2016 Apr 05. PMID: 27048189.
Copy Download .nbib Format: NLM
Comment: Pulmonary Embolism After Early Change From Rivaroxaban to Aspirin Following Total Knee Replacement in an Obese Patient.

The Annals of pharmacotherapy

Miyares MA.
PMID: 26251207
Ann Pharmacother. 2015 Oct;49(10):1179. doi: 10.1177/1060028015599794. Epub 2015 Aug 05.

No abstract available.

Cite
Miyares MA. Comment: Pulmonary Embolism After Early Change From Rivaroxaban to Aspirin Following Total Knee Replacement in an Obese Patient. Ann Pharmacother. 2015;49(10):1179doi: 10.1177/1060028015599794.
Miyares, M. A. (2015). Comment: Pulmonary Embolism After Early Change From Rivaroxaban to Aspirin Following Total Knee Replacement in an Obese Patient. The Annals of pharmacotherapy, 49(10), 1179. https://doi.org/10.1177/1060028015599794
Miyares, Marta A. "Comment: Pulmonary Embolism After Early Change From Rivaroxaban to Aspirin Following Total Knee Replacement in an Obese Patient." The Annals of pharmacotherapy vol. 49,10 (2015): 1179. doi: https://doi.org/10.1177/1060028015599794
Miyares MA. Comment: Pulmonary Embolism After Early Change From Rivaroxaban to Aspirin Following Total Knee Replacement in an Obese Patient. Ann Pharmacother. 2015 Oct;49(10):1179. doi: 10.1177/1060028015599794. Epub 2015 Aug 05. PMID: 26251207.
Copy Download .nbib Format: NLM
Extensive Bruising and Elevated Rivaroxaban Plasma Concentration in a Patient Receiving Cobicistat-Boosted Elvitegravir.

The Annals of pharmacotherapy

Yoong D, Naccarato M, Gough K.
PMID: 28351160
Ann Pharmacother. 2017 Aug;51(8):713-714. doi: 10.1177/1060028017702677. Epub 2017 Mar 28.

No abstract available.

Cite
Yoong D, Naccarato M, Gough K. Extensive Bruising and Elevated Rivaroxaban Plasma Concentration in a Patient Receiving Cobicistat-Boosted Elvitegravir. Ann Pharmacother. 2017;51(8):713-714doi: 10.1177/1060028017702677.
Yoong, D., Naccarato, M., & Gough, K. (2017). Extensive Bruising and Elevated Rivaroxaban Plasma Concentration in a Patient Receiving Cobicistat-Boosted Elvitegravir. The Annals of pharmacotherapy, 51(8), 713-714. https://doi.org/10.1177/1060028017702677
Yoong, Deborah, et al. "Extensive Bruising and Elevated Rivaroxaban Plasma Concentration in a Patient Receiving Cobicistat-Boosted Elvitegravir." The Annals of pharmacotherapy vol. 51,8 (2017): 713-714. doi: https://doi.org/10.1177/1060028017702677
Yoong D, Naccarato M, Gough K. Extensive Bruising and Elevated Rivaroxaban Plasma Concentration in a Patient Receiving Cobicistat-Boosted Elvitegravir. Ann Pharmacother. 2017 Aug;51(8):713-714. doi: 10.1177/1060028017702677. Epub 2017 Mar 28. PMID: 28351160.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 430 entries